Rezolute, Inc. (NASDAQ:RZLT) Receives Average Rating of "Buy" from Brokerages

Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have earned an average recommendation of "Buy" from the seven analysts that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $11.57.

A number of research firms have recently commented on RZLT. Maxim Group raised their target price on Rezolute from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Tuesday, August 6th. JMP Securities restated a "market outperform" rating and issued a $7.00 target price on shares of Rezolute in a research note on Friday, September 20th. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research note on Friday, September 27th. Guggenheim began coverage on Rezolute in a research note on Tuesday, August 27th. They issued a "buy" rating and a $11.00 target price for the company. Finally, BTIG Research lifted their price objective on Rezolute from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, September 10th.

Rezolute Stock Down 3.0 %

Shares of Rezolute stock traded down $0.15 during trading on Monday, hitting $4.78. 173,417 shares of the stock traded hands, compared to its average volume of 435,447. The stock has a market cap of $191.85 million, a price-to-earnings ratio of -4.25 and a beta of 1.19. The firm's fifty day moving average is $4.65 and its 200-day moving average is $3.95. Rezolute has a 52 week low of $0.72 and a 52 week high of $6.10.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). On average, analysts forecast that Rezolute will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

Institutional investors and hedge funds have recently modified their holdings of the business. Jeppson Wealth Management LLC bought a new stake in shares of Rezolute in the 2nd quarter worth $45,000. Virtu Financial LLC bought a new stake in shares of Rezolute in the 1st quarter worth $37,000. XTX Topco Ltd increased its holdings in shares of Rezolute by 205.8% in the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company's stock worth $145,000 after purchasing an additional 22,660 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Rezolute by 366.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company's stock worth $233,000 after purchasing an additional 42,597 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Rezolute in the 2nd quarter worth $255,000. Institutional investors own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.